CADTH
Canadian Agency for Drugs and Technologies in Health
| Type | NGO |
|---|---|
| Website | cadth.ca |
| Wikipedia |  |
| Year founded | 1989 |
| Location |
Ottawa, ON
 Canada
|
| Functions | Advocacy, Research |
| Funding sources | Governments or multi-govt organizations |
| Tags | technology health care |
| Summary | Created in 1989 by Canada’s federal, provincial, and territorial governments, CADTH was born from the idea that Canada needs a coordinated approach to assessing health technologies. The result was an organization that harnesses Canadian expertise from every region and produces evidence-informed solutions that benefit patients in jurisdictions across the country. CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system |
Flag this organization
Publications
CADTH: Canadian Agency for Drugs and Technologies in Health · 9 November 2023 English
March 30, 2022 Conditions for reimbursement Initiation: For patients who are Initiation: Eligibility for reimbursement biologic-naive who have yet to be of bimekizumab should be based on treated with any …
CADTH: Canadian Agency for Drugs and Technologies in Health · 8 November 2023 English
biologics with anti-TNF and • CADTH assessed the quality of the Cochrane systematic review and NMA using the anti-IL-12/23 biologics? AMSTAR 2 and ISPOR network meta-analysis tools and found a …
CADTH: Canadian Agency for Drugs and Technologies in Health · 6 November 2023 English
Stakeholder input from patient organizations has asked to “expand the project scope to include an evaluation of the safety and efficacy of newer biologics compared to ‘pre-requisite therapies’.” Has there …
CADTH: Canadian Agency for Drugs and Technologies in Health · 3 November 2023 English
Rapid Review
CADTH: Canadian Agency for Drugs and Technologies in Health · 2 November 2023 English
44 / 107 Nirmatrelvir-Ritonavir for the Treatment of COVID-19 Results of Clinical Evaluation The first study15 (Bajema et al., 2022) was conducted in the US and assessed the effectiveness of …
CADTH: Canadian Agency for Drugs and Technologies in Health · 2 November 2023 English
163 For transitions that pertain to time to next therapy (transitions 1, 3 and 5) the number of events and time to event 164 relate to the number of patients …
CADTH: Canadian Agency for Drugs and Technologies in Health · 2 November 2023 English
The aim is to ensure that CADTH reviews and the subsequent recommendations from the committee are more closely aligned with the needs of patients and their families through the incorporation …
CADTH: Canadian Agency for Drugs and Technologies in Health · 1 November 2023 English
FMEC Responses to Questions From the Drug Programs on Rivaroxaban Granules for Oral Suspension Rivaroxaban Granules for Oral Suspension FMEC Responses to Questions From the Drug Programs Table 1: Response …
CADTH: Canadian Agency for Drugs and Technologies in Health · 31 October 2023 English
05 / 76 Tocilizumab for the Treatment of Hospitalized Patients With COVID-19 Introduction and Rationale Objectives The objectives of this rapid systematic review are to determine the state of evidence …
CADTH: Canadian Agency for Drugs and Technologies in Health · 30 October 2023 English
08 / 151 Remdesivir for the Treatment of COVID-19 in the Inpatient Setting Introduction and Rationale Objectives The objective is to evaluate the efficacy and safety of remdesivir for the …